ESMO 2025 Will See Novel Agents Emerge and Standard Strategies Shift in GI Oncology

From further clarifying the role of PD-(L)1 inhibition in gastric cancer and colorectal cancer (CRC), to demonstrating the potential predictive value of minimal residual disease (MRD) negativity in late-stage colon cancer, gastrointestinal oncology data presented at the 2025 ESMO Congress are anticipated to challenge current standards of care (SOCs) and bring new questions to the forefront of research in the field. Additionally, data with KRAS inhibitors in pancreatic cancer are expected to further refine a treatment paradigm that has undergone much evolution in recent years.